Vogel G W, Vogel F
Br J Clin Pharmacol. 1983;16 Suppl 1(Suppl 1):103S-108S. doi: 10.1111/j.1365-2125.1983.tb02279.x.
We studied in a sleep laboratory the effects of bedtime 15 mg midazolam and 20 mg midazolam on the sleep and morning performance of healthy subjects with polygraphically verified sleep onset insomnia. Six subjects received 15 mg midazolam and six subjects received 20 mg midazolam for 14 consecutive nights which were preceded by a three-night placebo baseline and followed by a three-night placebo period. The medications were administered in a double-blind manner. The results were that both doses increased total sleep time, reduced sleep latency, reduced wake time after sleep onset and reduced the number of awakenings. There was no difference between the doses. Midazolam had its main effect by decreasing wake time in the first third of the night. We found no evidence of tolerance, drug withdrawal rebound insomnia, or drug-induced morning performance decrements. We did find evidence of an anterograde amnesia produced by the drug.
我们在睡眠实验室研究了睡前服用15毫克咪达唑仑和20毫克咪达唑仑对经多导睡眠图证实存在入睡性失眠的健康受试者睡眠及早晨表现的影响。六名受试者连续14晚服用15毫克咪达唑仑,六名受试者连续14晚服用20毫克咪达唑仑,服药前有三晚的安慰剂基线期,服药后有三晚的安慰剂期。药物以双盲方式给药。结果显示,两种剂量均增加了总睡眠时间,缩短了睡眠潜伏期,减少了睡眠开始后的觉醒时间,并减少了觉醒次数。两种剂量之间没有差异。咪达唑仑的主要作用是减少夜间前三分之一时间的觉醒时间。我们没有发现耐受性、药物戒断后反弹性失眠或药物引起的早晨表现下降的证据。我们确实发现了该药物产生顺行性遗忘的证据。